This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
bluebird bio (BLUE) Soars: Stock Adds 7.3% in Session
by Zacks Equity Research
bluebird bio (BLUE) was a big mover last session, as the company saw its shares rise more than 7% on the day.
Is Celgene (CELG) Looking to Take Over Juno Therapeutics?
by Zacks Equity Research
There are reports that Celgene (CELG) is in talks to acquire Juno Therapeutics to strengthen its portfolio given the recent series of setbacks.
Celgene Provides 2017 Preliminary Results & 2018 View
by Zacks Equity Research
Celgene Corporation (CELG) provided preliminary results for 2017 and upbeat guidance for 2018. The company suffered a few setbacks of late and is looking to bolster its pipeline.
4 Biotech Stocks That More Than Doubled This Year
by Zacks Equity Research
We take a look at a few biotech stocks whose price has increased more than 100% in 2017.
CAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & More
by Zacks Equity Research
The CAR-T therapy space has been in spotlight since Aug 2017 and the recent ASH meeting had further put focus on the same.
Company News For Dec 12, 2017
by Zacks Equity Research
Companies in the news are: KMG,ARGX,BPMC,BLUE
Bluebird's Shares Jump on Strong Data for CAR-T Therapy
by Zacks Equity Research
bluebird (BIRD) announced updated results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate- bb2121.
Novartis Reports Updated Results from Kymriah's JULIET Study
by Zacks Equity Research
Novartis (NVS) announced updated results from the JULIET study, which show Kymriah sustained complete responses at six months in adults with relapsed or refractory diffuse large B-cell lymphoma.
Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today
by Ryan McQueeney
Shares of Bluebird Bio (BLUE) were up nearly 20% in early morning trading Monday as investors responded to the company's announcement that its CAR-T candidate, bb2121, produced encouraging results in patients with a deadly blood cancer.
Gilead Sciences to Acquire Cell Design Labs for $567 Million
by Zacks Equity Research
Gilead Sciences, (GILD) and its subsidiary Kite announced that they have inked an agreement to acquire Cell Design Labs, for an upfront payment of $175 million.
Celgene CAR-T Therapy Gets Breakthrough Therapy Designation
by Zacks Equity Research
FDA grants Breakthrough Therapy Designation to Celgene's (CELG) chimeric antigen receptor T-cell (CAR-T) therapy candidate, bb2121.
Why Earnings Season Could Be Great for bluebird bio (BLUE)
by Zacks Equity Research
bluebird bio (BLUE) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
5 Top Performing Stocks of the Top ETF of August
by Sweta Killa
Inside the top performing ETF of August and its top stocks.
bluebird bio (BLUE) Looks Good: Stock Adds 11% in Session
by Zacks Equity Research
bluebird bio (BLUE) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Why Novatis' $475K CAR-T Cancer Treatment Is Actually Cheap
by Ryan McQueeney
The cancer treatment industry is celebrating a massive victory on Wednesday, as Novartis (NVS) received approval for its innovative new lymphoblastic leukemia treatment, making it the first approved CAR-T therapy in the world.
Indecision Won't Kill You, But It Will Take Your Money
by Kevin Cook
The pitfalls and powers of decision-making for traders and investors could be a model for everyone else.
Juno Therapeutics (JUNO) Continues Gains After Gilead-Kite Acquisition
by Ryan McQueeney
Shares of Juno Therapeutics (JUNO) continued to soar on Tuesday. The stock has now gained nearly 40% since the announcement that fellow CAR-T cancer therapy designer Kite Pharma (KITE) is being acquired by biotech behemoth Gilead Sciences (GILD).
Novartis CAR-T Therapy Drug Recommended by FDA Panel
by Zacks Equity Research
Novartis AG (NVS) announced that the FDA Oncologic Drugs Advisory Committee (ODAC) has unanimously (10-0) recommended the approval of immunocellular therapy candidate CTL019 (tisagenlecleucel).
bluebird bio (BLUE) Looks Good: Stock Adds 8.5% in Session
by Zacks Equity Research
bluebird bio saw its shares rise almost 9% on the day on the back of the company's recently released updated results from an ongoing early-stage clinical trial in relapsed/refractory multiple myeloma..
bluebird Stock Up on Positive Interim Multiple Myeloma Data
by Zacks Equity Research
bluebird bio (BLUE) reported encouraging interim phase I data on its anti-BCMA CAR T cell candidate, bb2121, in relapsed/refractory multiple myeloma patients.
Here's Why Bluebird Bio (BLUE) is Rallying Today
by Madeleine Johnson
On Thursday, shares of Bluebird Bio Inc. (BLUE) are rallying, up over 17% in midday trading after positive results came in for its experimental anti-BCMA CAR (chimeric antigen receptor) T-cell product candidate bb2121.
Bear of the Day: Conn's (CONN)
by David Bartosiak
With shoppers moving from bricks to clicks retailers are really struggling
Lessons Of A Biotech Blowup
by Brian Bolan
Biotechs are risky plays, even for the "smart money"